ÖZET
Amaç:
Huzursuz Bacak sendromu (HBS) sık görülen bir nörolojik hastalıktır. Levetirasetam (LEV) etkili ve geniş spektrumlu bir antiepileptik ilaçtır. Bu çalışmanın amacı epilepsi tanısı ile LEV monoterapisi alan hastalarda HBS sıklığını araştırmaktır.
Gereç ve Yöntem:
Epilepsi polikliniğinde takip edilen 1680 hastanın dosyası iki nörolog tarafından gözden geçirildi. En az 6 aydır LEV monoterapisi alan 107 hasta ve 120 sağlıklı kontrol çalışmaya alındı. HBS değerlendirmesi için Uluslararası Huzursuz Bacak Sendromu Çalışma Grubu’nun kriterleri göz önüne alındı.
Bulgular:
Sağlıklı kontrollerin ortalama yaşı 39,17±16,12 yıl iken, hastaların ortalama yaşı 38,26±17,39 yıldı. Her iki grup arasında yaş ve cinsiyet açısından istatistiksel anlamlı bir fark yoktu. Ortalama LEV kullanım süresi 28,34 aydı. LEV kullanım dozu 500-3000 mg/gün arasındaydı. HBS 7 (%5,83) sağlıklı kontrolde görülürken, LEV tedavisi öncesi 4 hasta (%3,73) HBS’ye sahipti. LEV tedavisine başladıktan sonra iki hastanın HBS semptomları kayboldu ve bu oran %1,87’ye geriledi. Tüm hasta grubunun biyokimyasal parametreleri normaldi, LEV tedavisi sonrasında semptomları rahatlamayan bir hastada periferik nöropati saptandı.
Sonuç:
LEV, HBS üzerinde tedavi edici etkiye sahip olabilir. Özellikle epilepsi ve HBS’nin birlikte görüldüğü komorbid durumlarda tercih edilebilir. LEV’nin HBS üzerindeki tedavi edici etkilerini daha iyi ortaya koyabilmek için longitudinal ve prospektif çalışmalara ihtiyaç vardır.
References
1
Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, Zucconi M, Ferri R, Trenkwalder C, Lee HB; International Restless Legss Syndrome Study Group. Restless legs syndrome/Willis-Ekbom diseasediagnostic criteria: updated International Restless Legss SyndromeStudy Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med 2014;15:860-73.
2
Tunc T, Karadag YS, Dogulu F, Inan LE. Predisposing factors of restless legs syndrome during pregnancy. Mov Disord 2007;22:627-31.
3
Burtscher C, Baxmann A, Kassubek J, Hornyak M, Matuja W, Schmutzhard E, Winkler AS. Prevalence of restless legs syndrome in an urban population of eastern Africa (Tanzania). J Neurol Sci 2014;346:121-7.
4
Sevim S, Dogu O, Kaleağası H, Aral M, Metin O, Camdeviren H. Correlation anxiety and depression symptoms in patients with restless legs syndrome: a population based survey. J Neurol Neurosurg Psychiatry 2014;75:226-30.
5
Ekbom KA. Restless legs. Acta Med Scand 1945;158:1-123
6
Walters AS. The International Restless Legs Syndrome Study Group. Toward a better definition of the restless legs syndrome. Mov Disord 1995;10:634-42.
7
Taşdemir M, Erdoğan H, Börü UT, Dilaver E, Kumaş A. Epidemiology of restless legs syndrome in Turkish adults on the western Black Sea coast of Turkey: A door-to-door study in a rural area. Sleep Med 2010;11:82-6.
8
Akpinar S. Treatment of Restless legs syndrome with L-Dopa benseraside. Arch Neurol 1982;39:739.
9
Iftikhar IH, Alghothani L, Trotti LM. Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis. Eur J Neurol 2017;24:1446-56.
10
Conti CF, Oliveira MM, Valbuza JS, Prado LB, Carvalho LB, Prado GF. Anticonvulsants to treat idiopathic restless legs syndrome: systematic review. ArqNeuropsiquiatr 2008;66(2B):431-5.
11
Telstad W, Sørensen O, Larsen S, Lillevold PE, Stensrud P, Nyberg-Hansen R. Treatment of the restless legs syndrome withcarbamazepine: a double blind study. Br Med J (Clin Res Ed) 1984;288:444-6.
12
Lundvall O, Abom PE, Holm R. Carbamazepine in restless legs. A controlled pilot study. Eur J Clin Pharmacol 1983;25:323-4.
13
Eisensehr I, Ehrenberg BL, Rogge Solti S, Noachtar S. Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid. J Neurol 2004;251:579-83.
14
Kocaturk M, Kutlu G, Kocaturk O, Erdal A, Inan LE. Restless Legs Syndrome Among the Epilepsy Patients who Took Carbamazepine or Valproic Acid Monotherapy. Epilepsy 2013;19:58-62.
15
Della Marca G, Vollono C, Mariotti P, Mazza M, Mennuni GF, Tonali P, Mazza S. Levetiracetam can be effective in the treatment of restless legs syndrome with periodic limb movements in sleep: report of two cases. J NeurolNeurosurg Psychiatry 2006;77:566-7.
16
Jain KK. An assessment of levetiracetam as an anti-epileptic drug. Expert Opin Investig Drugs 2000;9:1611-24.
17
Kutlu G, Gomceli YB, Unal Y, Inan LE. Levetiracetam monotherapy for late poststroke seizures in the elderly. Epilepsy Behav 2008;13:542-4.
18
Enggaard TP, Klitgaard NA, Sindrup SH. Specific effect of levetiracetam in experimental human pain models. Eur J Pain 2006;10:193-8.
19
Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA. Open-label pilot study of levetiracetam for the treatment of levodopa-induced dyskinesiasin Parkinson’s disease. Mov Disord 2005;20:1205-9.
20
Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electrographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
21
Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for Revised Classification of Epilepsies and Epileptic Syndromes. Epilepsia 1989;30:389-99.
22
Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, Ferini-Strambi L. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286-92.
23
Lajous M, Kurth T, Catzin-Kuhlmann A, Romieu I, Lopez-Ridaura R. Prevalence of restless legs syndrome in 69,830 Mexican women. Rev Invest Clin 2014;66:303-6.
24
Wali SO, Abaalkhail B. Prevalence of restless legs syndrome and associated risk factors among middle-aged Saudi population. Ann Thorac Med 2015;10:193-8.
25
Shi Y, Yu H, Ding D, Yu P, Wu D, Hong Z. Prevalence and risk factors of restless legs syndrome among Chinese adults in a rural community of Shanghai in China. PLoS One 2015;10:e0121215.
26
Sevim S, Dogu O, Camdeviren H, Bugdayci R, Sasmaz T, Kaleagasi H, Aral M, Helvaci I. Unexpectedly low prevalence and unusual characteristics of RLS in Mersin, Turkey. Neurology 2003;61:1562-9.
27
Altunayoglu Cakmak V, Koc B, Nuhoglu I, Topbas M, Ucuncu SY, Deger O, Kamburoglu S, Velioglu S. Prevalence of restless legs syndrome in Trabzon in the northeast Black Sea Region of Turkey: co-morbidities, socioeconomic factors and biochemical parameters. Neurol Res 2015;37:751-62.
28
Güler S, Caylan A, Nesrin Turan F, Dağdeviren N, Çelik Y. The prevalence of restless legs syndrome in Edirne and its districts concomitant comorbid conditions and secondary complications. Neurol Sci 2015;36:1805-12.
29
Byrne R, Sinha S, Chaudhuri KR. Restless legs syndrome: diagnosis and review of management options. Neuropsychiatr Dis Treat 2006;2:155-64.
30
UCB 2006. Efficacy and tolerability of levetiracetam in the treatment of restless legs syndrome: a double-blind placebo controlled crossover trial. Presentedat the meeting of the American Neurological Association; 2006.
31
Gagliano A, Arico I, Calarese T, Condurso R, Germano E, Cedro C, Spina E, Silvestri R. Restless Legs Syndrome in ADHD children: levetiracetam as a reasonable therapeutic option. Brain Dev 2011;33:480-6.
